Clinical Trial Update: Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase II study assessing neoadjuvant weekly paclitaxel and carboplatin followed by dose-dense epirubicin and cyclophosphamide in stage II-III triple negative br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED